Effects of low-dose aspirin in subjects with dyslipidemia

Lou, Guozhong; Chen, Jianming; Xia, Yu

doi:10.1186/s12944-016-0274-8

Cited by 6 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in the present study, administration of antiplatelets, aspirin and clopidogrel to obese rats for seven days produced significant reduction in lipid profile and FBS. Many studies were supported our findings, Lou et al, 2016 found that low dose of aspirin or clopidogrel had a beneficial effect in reducing serum LDL cholesterol, Lp (a) and Hs-CRP levels and improve CHD 28,29 . Platelets play a key role in atherogensis and thrombotic disorders.…”

Section: Fig 6: Photomicrograph Of the Rat Kidney Sections (Treatmensupporting

confidence: 80%

Untitled

2018

IJPSR

View full text Add to dashboard Cite

Introduction: Antiplatelets play a crucial role in improving many metabolic disorders and complications, including dyslipidemia, atherosclerosis, diabetes mellitus and cardiovascular diseases. The most common and effective antiplatelets used widely are aspirin and clopidogrel. The aim of this study is to evaluate the dyslipidemic and protective effects of aspirin and clopidogrel in obese rats. Materials and methods: 24 rats were divided into two groups, control (n = 6) (was taken normal chow) and the other group (n = 18) were allowed to eat beef tallow (90 g) and saturated fat (10 g) for 6 weeks to induce obesity. The second group was further classified to three subgroups, subgroup I (n = 6) was kept as obese group (n = 6) (positive control), subgroup II (n = 6) obese rats were treated with aspirin and subgroup III (n = 6) obese rats were treated with clopidogrel for 7 days. At the end of experiment blood samples were taken and lipid profile, FBS measured as well as body weight and the relative weights of liver were calculated. Histopathological samples were taken from different organs including liver, kidneys and heart. Results: Outcomes of this study showed that both tested drugs had dyslipidemic and protective effects as they significantly reduced cholesterol, TG, FBS as well as body and liver weight. They also ameliorated obesity-induced abnormalities in histopathological tissues with slight differences between the tested groups. Conclusion: It suggested from the findings of this study that both aspirin and clopidogrel might have dyslipidemic and protective effects in obese rats supported by histopathological findings.

show abstract

Section: Fig 6: Photomicrograph Of the Rat Kidney Sections (Treatmensupporting

confidence: 80%

Untitled

2018

IJPSR

View full text Add to dashboard Cite

show abstract

“…In addition, this study found that increased adherence to aspirin was associated with a reduced risk of GI cancer, similar to previous studies, suggesting that long-term aspirin use was associated with a protective effect against cancer, especially gastrointestinal tract tumors [ 28 ]. However, since long-term use of aspirin is also associated with an increased risk of gastrointestinal bleeding, it should be carefully considered [ 34 ], and whether it is used in combination with lipid-lowering agents will require further studies.…”

Section: Discussionmentioning

confidence: 99%

Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea

Han

Kim

2022

BMC Cancer

View full text Add to dashboard Cite

Background In aging populations, the number of people with high cholesterol levels is increasing. Appropriate management of high cholesterol levels with drugs such as statins may prevent secondary diseases. Despite many studies on the effects of statins on various types of cancer, the effectiveness of lipid-lowering therapy in preventing cancer remains controversial. This study aimed to evaluate its long-term effect on developing gastrointestinal (GI) cancer in patients with dyslipidemia. Methods This study used the National Health Insurance Sampling (NHIS) cohort data (2002–2015), which included patients with dyslipidemia without diabetes, and measured patients’ adherence to lipid-lowering therapy using the medication possession ratio. We used the Cox proportional hazard ratio (HR) to identify the association between the continuity of lipid-lowering therapy and the risk of GI cancer. We also evaluated the association between a combination of lipid-lowering drugs and a reduced risk of GI cancer. Results A total of 49,351 patients were diagnosed with dyslipidemia, of which 579 were diagnosed with GI cancer. Patients with higher adherence to lipid-lowering therapy had a significantly reduced risk of GI cancer compared to patients without drugs, and high adherence was associated with a reduced incidence of all types of GI cancer. Specifically, the combination of statins and ezetimibe or fibrates appears to reduce GI cancer risk effectively. Overall, the continuity of lipid-lowering therapy had a protective effect on GI cancer in middle-aged and elderly patients with dyslipidemia compared to non-users. Conclusions Our findings suggest that the continuity of lipid-lowering therapy is vital in patients with dyslipidemia. In addition, for individuals vulnerable to GI cancer, combination therapy may be associated with more effective protection against GI cancer. Healthcare providers need patient education and monitoring to improve drug adherence in patients with dyslipidemia.

show abstract

“…Goto-Kakizaki (GK) diabetic rats with low dose aspirin 100 mg/kg BW for 5 weeks showed significant improvement in glucose tolerance accompanied by significant decrease in insulinemia, pro-inflammatory prostaglandin, PGE2, the total cholesterol and lipoprotein levels [29]. Also, Lou et al [48] reported that low dose of aspirin had a beneficial effect in reducing serum low density lipoprotein, Lp (a) and Hs-CRP levels and improve coronary heart disease with slightly increase gastrointestinal bleeding risk. Lin and his coworkers [49] treated Sprague-Dawley (SD) rats with high fat diet for a 10-week with low dose of aspirin (5 mg/kg Bw) found that lowdose aspirin ameliorated hyperinsulinemia and hyperlipidemia, recovered activated partial thromboplastin and prothrombin time, prevent adhesion molecules expression and chemokine formation.…”

Section: Antidiabetic Effect Of Low Dose Aspirinmentioning

confidence: 98%

A possible Role of Salicylates in Diabetes Type II

Shehata

Ahmed

Nasr

2020

Zagazig Veterinary Journal

View full text Add to dashboard Cite

Type II diabetes mellitus is the most characteristic metabolic disorder, described by insulin resistance followed by pancreatic β -cell failure leading to hyperglycemia. Inflammation plays a critical role in both insulin resistance and pancreatic β-cell failure. Inflammation induce insulin resistance through stimulation of various serine kinases such as Inhibition of nuclear factor κβ kinase subunit β/ Nuclear factor-kappa Beta (IKK-β / NF-κβ) so, targeting the inflammation with anti-inflammatory agents and preventing insulin resistance may be a promising tool for type II diabetes management. But confirm this approach further researches and evaluation is required. Aspirin (acetyl salicylic acid), for recent use, offers a novel way for management of type II diabetes due to its anti-inflammatory properties and insulin-sensitizing action. Aspirin has the ability to ameliorate hyperglycemia, hyperlipidemia, hyperinsulinemia and insulin resistance and reduce proinflammatory cytokines by several mechanisms. Aspirin has the ability to treat and prevent cardiovascular diseases by inhibition of cyclooxegenase enzyme and act as antidiabetic due to its insulin sensitizing and anti-inflammatory properties. Therefore, aspirin is an effective antidiabetic therapy which is not only providing good glycemic control but also having antiinflammatory and antithrombotic effects. However, we should keep in mind the side effects that result from its prolonged use which are represented in gastric ulcer, hemorrhage and impairment of kidney function. This review summarizes the responsibility of inflammation in insulin resistance and the role of aspirin as antiplatelets and antidiabetic drug.

show abstract

Effects of low-dose aspirin in subjects with dyslipidemia

Cited by 6 publications

References 21 publications

Untitled

Untitled

Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea

A possible Role of Salicylates in Diabetes Type II

Contact Info

Product

Resources

About